{
  "source": "PA-Notification-Firazyr-icatibant-Sajazir.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1032-13\nProgram Prior Authorization/Notification\nMedications Firazyr® (icatibant)*, icatibant, Sajazir™ (icatibant)*\nP&T Approval Date 11/2011, 11/2012, 11/2013, 8/2014, 8/2015, 7/2016, 7/2017, 7/2018,\n7/2019, 7/2020, 7/2021, 7/2022, 4/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nFirazyr (icatibant)* is a bradykinin B2 receptor antagonist indicated for treatment of acute\nattacks of hereditary angioedema (HAE) in adults 18 years of age and older. Sajazir (icatibant)*\ninjection is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of HAE\nin adults 18 years of age and older.\n2. Coverage Criteriaa:\nA. Firazyr*, icatibant, or Sajazir* will be approved based on all of the following criteria:\n1. Diagnosis of hereditary angioedema (HAE)\n-AND-\n2. Prescribed for the treatment of acute HAE attacks\n-AND-\n3. Not used in combination with other products indicated for the acute treatment of HAE\nattacks (e.g., Berinert, Kalbitor, or Ruconest)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n* Firazyr (brand) and Sajazir are typically excluded from coverage. Coverage reviews may be in\nplace if required by law or the benefit plan.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n© 2025 UnitedHealthcare Services, Inc.\n1\n4. References:\n1. Firazyr [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; January 2024.\n2. Sajazir [package insert]. Cambridge, CB3 0FA",
    "\n© 2025 UnitedHealthcare Services, Inc.\n1\n4. References:\n1. Firazyr [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; January 2024.\n2. Sajazir [package insert]. Cambridge, CB3 0FA, United Kingdom: Cycle Pharmaceuticals Ltd;\nFebruary 2024.\nProgram Prior Authorization/Notification - Firazyr (icatibant), Sajazir (icatibant)\nChange Control\n11/2013 Annual review. Removed requirement for Type I or II HAE. Changed\nauthorization duration from 12 months to 60 months.\n8/2014 Annual review. Added an additional criterion that does not allow\ncombination use with other HAE acute treatments. Decreased authorization\nfrom 60 months to 12 months. Updated Background and References.\n8/2015 Annual review. No change.\n7/2016 Annual review with no changes to the clinical criteria. Updated background\nand references.\n7/2017 Annual review. No changes to program.\n7/2018 Annual review. No changes to program.\n7/2019 Annual review. No changes to program.\n7/2020 Annual review. No changes to coverage criteria.\n7/2021 Annual review. No changes to coverage criteria. Reference updated.\n7/2022 Annual review with no changes to coverage criteria. Added state mandate\nfootnote. Updated reference.\n4/2023 Added Sajazir, updated background, and updated references.\n2/2024 Added coverage exclusion statement for brand Firazyr and Sajazir. Revised\nwording of criteria without changes to clinical intent.\n2/2025 Annual review with no changes to coverage criteria. Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}